MTOR and glioblastoma: A phase II clinical trial is currently being conducted (NCT05183204, https://clinicaltrials.gov/study/NCT05183204, accessed on 27 October 2024), combining the PI3K/mTOR inhibitor paxalisib with a ketogenic diet plus metformin in patients with newly diagnosed and recurrent glioblastoma.